US › Healthcare

Alzamend Neuro Inc (ALZN)

US · Healthcare · Biotechnology

$1.30+1.56%

Last close · 2026-10-16

Latest quarter · ended 2026-07-31

Revenue

Net profit

$-3.0M

EPS

$-0.68

EPS estimate

$-0.56

EPS came in at -0.68 against a street estimate of -0.56 — a miss of 21.4%.

Key statistics

Market cap

$6.3M

Forward P/E

0.0

P/B

1.61

Book value

$1.20

EPS (TTM)

$-2.30

52-week high

$2.68

52-week low

$0.84

50-day MA

$1.59

200-day MA

$1.53

Beta

0.27

Analyst view

Analysts rate Alzamend Neuro Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $26.00.

Shareholding

Insiders

2.66%

Institutions

56.35%

Largest institutional holders

Fund	Stake
Kingsbury Capital Investment Advisors LLC	27.54%
KMT WEALTH MANAGEMENT, LLC	27.54%
Geode Capital Management, LLC	0.55%
Vanguard Fiduciary Trust Co	0.44%
Vanguard Capital Management, LLC	0.16%
Tower Research Capital LLC	0.07%
UBS Group AG	0.05%
BlackRock Inc	0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alzamend Neuro Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.